☆ 4.8 Meeting Abstract

SERENA-4: A Phase III comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive/HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease

CANCER RESEARCH (2022)

Get Full Text
Add to Collection

Journal

CANCER RESEARCH
Volume 82, Issue 4, Pages -

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1538-7445.SABCS21-OT2-11-06

Keywords

-

Categories

Oncology

Funding

  1. AstraZeneca

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.